In acute STEMI, which initial therapy has the strongest evidence for reducing mortality?

In acute STEMI, which initial therapy has the strongest evidence for reducing mortality?

• A. Oxygen therapy
• B. Beta-blocker infusion
• C. Thrombolysis with tissue plasminogen activator
• D. Aspirin administration immediately

Answer: (D)

In the early management of a STEMI, rapidly inhibiting platelet aggregation to prevent further thrombus growth has the strongest impact on survival. Aspirin does this by irreversibly inhibiting cyclooxygenase-1 in platelets, which blocks thromboxane A2 production and dramatically reduces platelet clumping at the ruptured plaque. This effect occurs quickly and has been shown to lower mortality in major MI trials, making aspirin universally beneficial as soon as STEMI is suspected or diagnosed. Other options have important roles in specific contexts but do not match the universal mortality benefit of early aspirin. Oxygen therapy helps only if a patient is hypoxic; giving it to normoxic patients hasn’t shown mortality improvement. Beta-blockers can reduce myocardial oxygen demand and may help, but IV use in the hyperacute phase carries risks like hypotension and bradycardia, and the survival benefit is not as robust or universal as aspirin. Thrombolysis with tissue plasminogen activator can reduce mortality if given promptly, but its benefit depends on time window and bleeding risk, and aspirin’s benefit applies across reperfusion strategies.

In the early management of a STEMI, rapidly inhibiting platelet aggregation to prevent further thrombus growth has the strongest impact on survival. Aspirin does this by irreversibly inhibiting cyclooxygenase-1 in platelets, which blocks thromboxane A2 production and dramatically reduces platelet clumping at the ruptured plaque. This effect occurs quickly and has been shown to lower mortality in major MI trials, making aspirin universally beneficial as soon as STEMI is suspected or diagnosed.

Other options have important roles in specific contexts but do not match the universal mortality benefit of early aspirin. Oxygen therapy helps only if a patient is hypoxic; giving it to normoxic patients hasn’t shown mortality improvement. Beta-blockers can reduce myocardial oxygen demand and may help, but IV use in the hyperacute phase carries risks like hypotension and bradycardia, and the survival benefit is not as robust or universal as aspirin. Thrombolysis with tissue plasminogen activator can reduce mortality if given promptly, but its benefit depends on time window and bleeding risk, and aspirin’s benefit applies across reperfusion strategies.